← Back to Home

Designing Protein Drugs from Scratch: Astellas Partners with AI Proteins in Deal Potentially Worth Over $400 Million

Astellas will obtain exclusive global licenses to drug candidates from the collaboration, betting on the ability to design miniproteins using AI. However, the upfront payment, targets and indications have not been disclosed, and the deal’s size does not mean efficacy has been validated.

By SURL BioNews

If developers could first define what a drug needs to do and then design a corresponding protein, biologic drug development could gain another approach. Astellas and Boston biotech company AI Proteins announced a collaboration on October 21 to use artificial intelligence to design miniproteins from scratch and identify new therapeutic candidates.

According to AI Proteins’ announcement, the agreement was signed with Astellas Innovation Management, an Astellas subsidiary. AI Proteins could receive upfront and milestone payments totaling more than $400 million, plus royalties on future net product sales. The upfront payment was not disclosed, so this potential total should not be interpreted as investment already received.

The division of responsibilities begins with drug discovery: Astellas selects multiple targets, and AI Proteins designs and optimizes candidate molecules. Astellas will obtain exclusive global licenses to the collaboration’s resulting candidates and will be responsible for subsequent development, regulatory submissions and commercialization. Publicly available information has not yet disclosed the specific targets or indications, nor have any drug candidate names been announced.

At the core of the technology is “de novo” design. According to AI Proteins, the platform uses computational methods to create new protein structures based on therapeutic needs, then adjusts their ability to bind to specified targets and other molecular properties. AI serves here as a tool for designing drug molecules; the products being developed are miniproteins with specific biological effects.

The company believes this design approach could improve protein stability and allow exploration of different routes of administration. However, these remain properties the platform aims to achieve and cannot be treated as established advantages of products from this collaboration. The announcement provided no quantitative binding data, animal efficacy results or human trial results for the collaboration’s molecules, and did not describe the AI models’ training data or validation methods.

The agreement gives Astellas an opportunity to incorporate a new molecular design approach into early research and development, but multiple hurdles remain between binding to a target and working safely in patients. The next information more useful for assessing progress will be experimental evidence for specific candidate molecules and how they meet the safety and quality requirements needed to enter human trials.

References

  1. FirstWord Pharma